Cargando…

Long-term risk of a major cardiovascular event by apoB, apoA-1, and the apoB/apoA-1 ratio—Experience from the Swedish AMORIS cohort: A cohort study

BACKGROUND: Elevated apolipoprotein B (apoB) and elevated apoB/apoA-1 ratio increase the risk of myocardial infarction (MI) and stroke, whereas high apoA-1 is protective. We study how these apolipoproteins are associated with major adverse cardiovascular events (MACEs), whether apoA-1 contributes to...

Descripción completa

Detalles Bibliográficos
Autores principales: Walldius, Göran, de Faire, Ulf, Alfredsson, Lars, Leander, Karin, Westerholm, Peter, Malmström, Håkan, Ivert, Torbjörn, Hammar, Niklas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8635349/
https://www.ncbi.nlm.nih.gov/pubmed/34851955
http://dx.doi.org/10.1371/journal.pmed.1003853
_version_ 1784608283477147648
author Walldius, Göran
de Faire, Ulf
Alfredsson, Lars
Leander, Karin
Westerholm, Peter
Malmström, Håkan
Ivert, Torbjörn
Hammar, Niklas
author_facet Walldius, Göran
de Faire, Ulf
Alfredsson, Lars
Leander, Karin
Westerholm, Peter
Malmström, Håkan
Ivert, Torbjörn
Hammar, Niklas
author_sort Walldius, Göran
collection PubMed
description BACKGROUND: Elevated apolipoprotein B (apoB) and elevated apoB/apoA-1 ratio increase the risk of myocardial infarction (MI) and stroke, whereas high apoA-1 is protective. We study how these apolipoproteins are associated with major adverse cardiovascular events (MACEs), whether apoA-1 contributes to this association, and whether abnormal values occur decades before such events develop. METHODS AND FINDINGS: In the Swedish AMORIS (Apolipoprotein-related MOrtality RISk) cohort study, 137,100 men and women aged 25–84 years were followed an average 17.8 years. ApoB, apoA-1, and the apoB/apoA-1 ratio were analysed in relation to MACEs (non-fatal MI, stroke, and cardiovascular [CV] mortality), yielding 22,473 events. Hazard ratios (HRs) were estimated using Cox regression. Kaplan–Meier estimates were used to investigate the relationship of MACEs with increasing quintiles of the apoB/apoA-1 ratio in all age groups for both sexes. In nested case–control analyses, cases were randomly matched to age- and sex-matched controls, yielding population trajectories for apolipoproteins. Increased level of apoB and increased apoB/apoA-1 ratio were associated with risk of MACE and all clinical sub-components in both men and women across all ages (10th versus first decile in both sexes combined: HR 1.7 for MACE and 2.7 for non-fatal MI). Decreased values of apoA-1 potentiated the impact of apoB at all levels of apoB (on average across apoB range: 40% increase in HR for MACE and 72% increase in HR for non-fatal MI), indicating that the apoB/apoA-1 ratio covers a broader range of persons with dyslipidaemia at risk than apoB alone. In both men and women, MACEs occurred earlier on average for each increasing quintile of the apoB/apoA-1 ratio. Individuals with the highest levels of apoB/apoA-1 ratio experienced CV events on average several years earlier than those with lower ratios. Higher apoB/apoA-1 ratio in cases of MACE versus controls was seen already about 20 years before the event. A limitation of this study was that adjustment for tobacco smoking and hypertension was only possible in a small validation study. CONCLUSIONS: An imbalance between apoB and apoA-1 resulting in an increased apoB/apoA-1 ratio is strongly associated with the outcome MACE and its sub-components, in both men and women of all ages. An increased apoB/apoA-1 ratio already 2 decades before events calls for early recognition and primary prevention. Simple evidence-based cut values should be considered in future cardiovascular guidelines.
format Online
Article
Text
id pubmed-8635349
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-86353492021-12-02 Long-term risk of a major cardiovascular event by apoB, apoA-1, and the apoB/apoA-1 ratio—Experience from the Swedish AMORIS cohort: A cohort study Walldius, Göran de Faire, Ulf Alfredsson, Lars Leander, Karin Westerholm, Peter Malmström, Håkan Ivert, Torbjörn Hammar, Niklas PLoS Med Research Article BACKGROUND: Elevated apolipoprotein B (apoB) and elevated apoB/apoA-1 ratio increase the risk of myocardial infarction (MI) and stroke, whereas high apoA-1 is protective. We study how these apolipoproteins are associated with major adverse cardiovascular events (MACEs), whether apoA-1 contributes to this association, and whether abnormal values occur decades before such events develop. METHODS AND FINDINGS: In the Swedish AMORIS (Apolipoprotein-related MOrtality RISk) cohort study, 137,100 men and women aged 25–84 years were followed an average 17.8 years. ApoB, apoA-1, and the apoB/apoA-1 ratio were analysed in relation to MACEs (non-fatal MI, stroke, and cardiovascular [CV] mortality), yielding 22,473 events. Hazard ratios (HRs) were estimated using Cox regression. Kaplan–Meier estimates were used to investigate the relationship of MACEs with increasing quintiles of the apoB/apoA-1 ratio in all age groups for both sexes. In nested case–control analyses, cases were randomly matched to age- and sex-matched controls, yielding population trajectories for apolipoproteins. Increased level of apoB and increased apoB/apoA-1 ratio were associated with risk of MACE and all clinical sub-components in both men and women across all ages (10th versus first decile in both sexes combined: HR 1.7 for MACE and 2.7 for non-fatal MI). Decreased values of apoA-1 potentiated the impact of apoB at all levels of apoB (on average across apoB range: 40% increase in HR for MACE and 72% increase in HR for non-fatal MI), indicating that the apoB/apoA-1 ratio covers a broader range of persons with dyslipidaemia at risk than apoB alone. In both men and women, MACEs occurred earlier on average for each increasing quintile of the apoB/apoA-1 ratio. Individuals with the highest levels of apoB/apoA-1 ratio experienced CV events on average several years earlier than those with lower ratios. Higher apoB/apoA-1 ratio in cases of MACE versus controls was seen already about 20 years before the event. A limitation of this study was that adjustment for tobacco smoking and hypertension was only possible in a small validation study. CONCLUSIONS: An imbalance between apoB and apoA-1 resulting in an increased apoB/apoA-1 ratio is strongly associated with the outcome MACE and its sub-components, in both men and women of all ages. An increased apoB/apoA-1 ratio already 2 decades before events calls for early recognition and primary prevention. Simple evidence-based cut values should be considered in future cardiovascular guidelines. Public Library of Science 2021-12-01 /pmc/articles/PMC8635349/ /pubmed/34851955 http://dx.doi.org/10.1371/journal.pmed.1003853 Text en © 2021 Walldius et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Walldius, Göran
de Faire, Ulf
Alfredsson, Lars
Leander, Karin
Westerholm, Peter
Malmström, Håkan
Ivert, Torbjörn
Hammar, Niklas
Long-term risk of a major cardiovascular event by apoB, apoA-1, and the apoB/apoA-1 ratio—Experience from the Swedish AMORIS cohort: A cohort study
title Long-term risk of a major cardiovascular event by apoB, apoA-1, and the apoB/apoA-1 ratio—Experience from the Swedish AMORIS cohort: A cohort study
title_full Long-term risk of a major cardiovascular event by apoB, apoA-1, and the apoB/apoA-1 ratio—Experience from the Swedish AMORIS cohort: A cohort study
title_fullStr Long-term risk of a major cardiovascular event by apoB, apoA-1, and the apoB/apoA-1 ratio—Experience from the Swedish AMORIS cohort: A cohort study
title_full_unstemmed Long-term risk of a major cardiovascular event by apoB, apoA-1, and the apoB/apoA-1 ratio—Experience from the Swedish AMORIS cohort: A cohort study
title_short Long-term risk of a major cardiovascular event by apoB, apoA-1, and the apoB/apoA-1 ratio—Experience from the Swedish AMORIS cohort: A cohort study
title_sort long-term risk of a major cardiovascular event by apob, apoa-1, and the apob/apoa-1 ratio—experience from the swedish amoris cohort: a cohort study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8635349/
https://www.ncbi.nlm.nih.gov/pubmed/34851955
http://dx.doi.org/10.1371/journal.pmed.1003853
work_keys_str_mv AT walldiusgoran longtermriskofamajorcardiovasculareventbyapobapoa1andtheapobapoa1ratioexperiencefromtheswedishamoriscohortacohortstudy
AT defaireulf longtermriskofamajorcardiovasculareventbyapobapoa1andtheapobapoa1ratioexperiencefromtheswedishamoriscohortacohortstudy
AT alfredssonlars longtermriskofamajorcardiovasculareventbyapobapoa1andtheapobapoa1ratioexperiencefromtheswedishamoriscohortacohortstudy
AT leanderkarin longtermriskofamajorcardiovasculareventbyapobapoa1andtheapobapoa1ratioexperiencefromtheswedishamoriscohortacohortstudy
AT westerholmpeter longtermriskofamajorcardiovasculareventbyapobapoa1andtheapobapoa1ratioexperiencefromtheswedishamoriscohortacohortstudy
AT malmstromhakan longtermriskofamajorcardiovasculareventbyapobapoa1andtheapobapoa1ratioexperiencefromtheswedishamoriscohortacohortstudy
AT iverttorbjorn longtermriskofamajorcardiovasculareventbyapobapoa1andtheapobapoa1ratioexperiencefromtheswedishamoriscohortacohortstudy
AT hammarniklas longtermriskofamajorcardiovasculareventbyapobapoa1andtheapobapoa1ratioexperiencefromtheswedishamoriscohortacohortstudy